Press brief by Tony Green, MD, PhD of the Cambridge Institute for Medical Research, Cambridge, UK, at the 2016 Annual…
Browsing: Acute Lymphoblastic Leukemia
Giuseppe Saglio, MD of the University of Turin, Turin, Italy provides an overview of the results of the Phase III…
In this Ask the Expert segment, Terry is concerned about his mothers treatment and side effects. He wants to know…
Evan Yu, MD of Seattle Cancer Care notes that some patients saw dramatic improvement in IMvigor210 trial
From our MPN Ask the Expert series, Patient Power viewer, Jane, asks a question about using iron supplements for MPN…
In this Ask the Expert segment, Terry is concerned about his mothers treatment and side effects. He wants to know…
POPLAR trial success leads to larger OAK study
Autoimmune can be delayed in immunotherapy
Alexander Spira, MD of the Cleveland Clinic discusses the results of Phase II POPLAR trial evaluating Atezolizumab in advanced NSCLC
Nathan Pennell, MD of Cleveland Clinic discusses his experience with Nivolumab and Pembrolizumab in the second line therapy of your…
Omid Hamid, MD of the Angeles Clinic discusses the phase III NEMO trial and the novel MEK inhibitor Binimetinib
Petros Grivas, MD of Cleveland Clinic discusses the efficacy of Atezolizumab within cohort 2 of IMvigor210
Arjun V. Balar, MD of NYU Langone Medical Center discusses the percentage of patient with urothelial cancer that are cisplatin…
Dr. Fadi Braiteh, MD of Comprehensive Cancer Centers of Nevada describers the differences in Squamous Cell Carcinomas versus the Non-Squamous…
Dr. Ramaswamy Govindan, MD of the Washington University Medical School gives an update on BRAF in NSCLC from ASCO 2016
Dr. Heather Wakelee, MD of the Stanford School of Medicine outlines the best way to test newly diagnosed NSCLC in…
Jeffrey Jones, MD, MPH from the Ohio State University, Columbus, OH discussing the characteristics and mode of action of Ibrutinib.…
Jeffrey Jones, MD, MPH from the Ohio State University, Columbus, OH discusses the current thought on treating relapsed and refractory…
Mohamad Mohty, MD, PhD from Saint-Antoine Hospital, Paris, France discussing treatment options for relapsed and refractory myeloma at the European…
Giuseppe Saglio, MD from University of Turin, Turin, Italy discusses the influence of TKI therapy on the treatment of chronic…
Antonio Palumbo, MD from the University of Turin, Turin, Italy talks about when daratumumab will be available in combination with…
Haifa Kathrin Al-Ali, MD from University of Leipzig, Leipzig, Germany discusses research into JAK inhibitors specifically Ruxolitinib, Pacritinib, and Momelotinib.…
Antonio Palumbo, MD from the University of Turin, Turin, Italy discusses the place of daratumumab in the current treatment landscape…
Niels van de Donk, MD, PhD from the University Medical Center, Amsterdam, Netherlands discusses three trials of daratumumab in multiple…
Haifa Kathrin Al-Ali, MD from University of Leipzig, Leipzig, Germany discusses janus kinase (JAK) inhibitors at the European Hematology Association…
Josep-Maria Ribera, MD, PhD from Germans Trias i Pujol University Hospital, Barcelona, Spain outlines the importance of blinatumomab and inotuzumab…
Shaji Kumar, MD from the Mayo Clinic, Rochester, MN discusses the current research on immunotherapy in multiple myeloma (MM). The…
Josep-Maria Ribera, MD, PhD from Germans Trias i Pujol University Hospital, Barcelona, Spain outlines his talk on minimal residual disease…
Antonio Palumbo, MD from the University of Turin, Turin, Italy gives an overview of the results of the Phase III…
Josep-Maria Ribera, MD, PhD from Germans Trias i Pujol University Hospital, Barcelona, Spain outlines the clinical practice of acute lymphoblastic…
Shaji Kumar, MD from the Mayo Clinic, Rochester, MN discusses venetoclax and the future of treatment of multiple myeloma (MM).…
Simon Rule, MD from Derriford Hospital, Plymouth, UK discusses current mantle cell lymphoma (MCL) news, including the novel results from…
Valeria Santini, MD from University of Florence, Florence, Italy outlines the mode of action of hypomethylating agents – azacitidine and…
Michael Hallek, MD from the University of Cologne, Cologne, Germany discusses the debate around whether chronic lymphocytic leukemia (CLL) is…
Marek Trneny, MD, PhD from Charles University General Hospital, Prague, Czech Republic gives an overview of his talk on the…
Katja Weisel, MD from University Hospital Tuebingen, Tuebingen, Germany discusses the slowly progressing myeloma and outlines how there are clear…
Valeria Santini, MD from University of Florence, Florence, Italy discusses the treatment of myelodysplastic syndromes (MDS). In Europe azacitidine is…
Simon Rule, MD from Derriford Hospital, Plymouth, UK outlines his presentation on his work with ibrutinib. Prof Rule discusses the…
Anna Schuh, MD, PhD, from the University of Oxford, discusses the importance of genomic analysis in chronic lymphocytic leukemia (CLL)…
Charles Craddock, CBE, FRCP, FRCPath, DPhil, from Queen Elizabeth Hospital, Birmingham, UK provides an overview of his talk on allogeneic…
Gail Roboz, MD from Weill Medical College of Cornell University, New York, NY outlines the limited progress in acute myeloid…
Charles Craddock, CBE, FRCP, FRCPath, DPhil, from Queen Elizabeth Hospital, Birmingham, UK discusses when a transplant is the most suitable…
Charles Craddock, CBE, FRCP, FRCPath, DPhil, from Queen Elizabeth Hospital, Birmingham, UK explains how epigenetic drugs may have a capacity…
Anna Schuh, MD, PhD, from the University of Oxford, Oxford, UK, gives an overview of the CLL pilot run by…
Dr. Alexander Spira, MD of Virginia Cancer Specialists goes over the risk and benefit to blocking PD-L2
Dr. Robert Dreicer, MD of the University of Virginia highlights small molecule inhibitor trials within urothelial cancer
Dr. Arjun V. Balar, MD of NYU Langone Medical Center discusses using deficient mismatch repair in PD-L1 therapy for urothelial…
Dr. Evan Yu, MD of Seattle Cancer Care Alliance notes that some patient populations may respond better to atezolizumab and…
Dr. Omid Hamid, MD of The Angeles Clinic discusses new predictive markers in immunotherapy for melanoma
Dr. Petros Grivas, MD of Cleveland Clinic outlines how the higher levels of PD-L1 expression correlates with higher response rates